ASH: BPMC To Make A Mark; FATE So Far, So Good; Watch Out For SYRS, BIVV

(RTTNews) - The 59th American Society of Hematology (ASH) Annual Meeting is just around the corner. More than 250 pharmaceutical companies will be participating in the meeting which will be held between December 9 and December 12, 2017, at Atlanta, Georgia.

Here's another list of companies that will be presenting new data or updated analyses from their hematology clinical trials.

It's been a banner year for Blueprint Medicines Corp. (BPMC), whose stock price has climbed a whopping 148% year-to-date.

The Company is developing a new generation of targeted and potent kinase medicines to improve the lives of patients with genomically defined diseases.

BLU-285 and BLU-554 are the two lead drug candidates of the Company, both of which are under phase I clinical trials.

BLU-285 is being explored in the indications of advanced gastrointestinal stromal tumors and advanced systemic mastocytosis. BLU-554 is in development for hepatocellular carcinoma.

At the American Society of Hematology (ASH) Annual Meeting, on December 10, 2017, the Company will be presenting updated data from its ongoing phase I clinical trial of BLU-285 for the treatment of advanced systemic mastocytosis.

Systemic mastocytosis (SM) is a form of mastocytosis in which mast cells accumulate in internal tissues and organs such as the liver, spleen, bone marrow, and small intestines. (Source: NIH).

BPMC closed Monday's (Dec.4) trading at $69.71, down 4.27%.

Shares of Fate Therapeutics Inc. (FATE) are up an impressive 66% year-to-date.

The Company is focused on developing programmed cellular immunotherapies for cancer and immune disorders.

At the ASH Meeting on December 11, 2017, the Company will be presenting Day 100 efficacy data from its phase I study of ProTmune for the prevention of acute graft-versus-host disease (GvHD) in patients with hematologic malignancies undergoing matched unrelated donor hematopoietic cell transplantation (HCT), dubbed PROTECT.

The phase II stage of the PROTECT study was initiated as recently as September based on recommendations of an independent data monitoring committee. All subjects met the Day 28 safety objectives of neutrophil engraftment and survival, and reached Day 28 without any events of graft failure or serious adverse events related to ProTmune.

FATE closed Monday's (Dec.4) trading at $4.17, down 5.01%.

Shares of Syros Pharmaceuticals Inc. (SYRS) are down 40% from their 52-week high of $24.38 recorded in August.

The Company is pioneering a new area of medicine focused on controlling the expression of genes. When genes are expressed at the wrong time or in wrong amounts, the function of the cell is altered, which could lead to a range of diseases.

The Company's drug candidates are SY-1425, under phase II clinical trial in genomically defined subsets of patients with acute myeloid leukemia and myelodysplastic syndrome, and SY-1365, in a phase I clinical trial, for patients with advanced solid tumors, including transcriptionally dependent cancers such as triple negative breast, small cell lung and ovarian cancers.

On December 10, 2017, at the ASH meeting, the Company will be reporting initial clinical data from the phase II trial of SY-1425.

SYRS closed Monday's (Dec.4) trading at $14.60, down 5.19%.

Shares of Bioverativ Inc. (BIVV) are nearly 22% down from their 52-week high of $64.41 set in July.

The Company is focused on developing therapies for the treatment of people with hemophilia and other rare blood disorders.

Bioverativ has two marketed products, ELOCTATE and ALPROLIX, and a couple of clinical compounds.

A phase I/IIa trial of BIVV001 for hemophilia A is underway, and the Company is on track to initiate phase III studies for BIVV009 in cold agglutinin disease (CAgD) by year end.

At the ASH Meeting, the Company will be making presentations, highlighting its scientific innovation in hemophilia, cold agglutinin disease, sickle cell disease and beta-thalassemia.

BIVV closed Monday's (Dec.4) trading at $50.30, up 1.90%.